(Q44636550)

English

Adding interferon-α to octreotide slows tumour progression compared with octreotide alone but evidence is lacking for improved survival in people with disseminated midgut carcinoid tumours

scientific article published on December 1, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Adding interferon-alpha to octreotide slows tumour progression compared with octreotide alone but evidence is lacking for improved survival in people with disseminated midgut carcinoid tumours (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Adding interferon-α to octreotide slows tumour progression compared with octreotide alone but evidence is lacking for improved survival in people with disseminated midgut carcinoid tumours (English)

1 reference

10.1016/J.CTRV.2003.07.002

https://api.crossref.org/works/10.1016/J.CTRV.2003.07.002

26 March 2024

carcinoid tumor

1 reference

based on heuristic

inferred from title

tumor progression

1 reference

based on heuristic

inferred from title

1 reference

10.1016/J.CTRV.2003.07.002

https://api.crossref.org/works/10.1016/J.CTRV.2003.07.002

26 March 2024

Bertram Wiedenmann

2

object named as

Bertram Wiedenmann

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14585268

26 March 2024

author name string

Ulrich Frank Pape

1

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14585268

26 March 2024

publication date

1 December 2003

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

full work available at URL

https://api.elsevier.com/content/article/PII:S0305737203001877?httpAccept=text/xml

1 reference

10.1016/J.CTRV.2003.07.002

https://api.crossref.org/works/10.1016/J.CTRV.2003.07.002

26 March 2024

https://api.elsevier.com/content/article/PII:S0305737203001877?httpAccept=text/plain

1 reference

10.1016/J.CTRV.2003.07.002

https://api.crossref.org/works/10.1016/J.CTRV.2003.07.002

26 March 2024

Cancer Treatment Reviews

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

565-569

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

A 5-decade analysis of 13,715 carcinoid tumors

1

1 reference

10.1016/J.CTRV.2003.07.002

https://api.crossref.org/works/10.1016/J.CTRV.2003.07.002

26 March 2024

Carcinoid tumour

2

1 reference

10.1016/J.CTRV.2003.07.002

https://api.crossref.org/works/10.1016/J.CTRV.2003.07.002

26 March 2024

Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumors: general recommendations by a consensus workshop

4

1 reference

10.1016/J.CTRV.2003.07.002

https://api.crossref.org/works/10.1016/J.CTRV.2003.07.002

26 March 2024

Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours

5

1 reference

10.1016/J.CTRV.2003.07.002

https://api.crossref.org/works/10.1016/J.CTRV.2003.07.002

26 March 2024

The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors

6

1 reference

10.1016/J.CTRV.2003.07.002

https://api.crossref.org/works/10.1016/J.CTRV.2003.07.002

26 March 2024

Effects of Leukocyte Interferon on Clinical Symptoms and Hormone Levels in Patients with Mid-Gut Carcinoid Tumors and Carcinoid Syndrome

8

1 reference

10.1016/J.CTRV.2003.07.002

https://api.crossref.org/works/10.1016/J.CTRV.2003.07.002

26 March 2024

Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa

10

1 reference

10.1016/J.CTRV.2003.07.002

https://api.crossref.org/works/10.1016/J.CTRV.2003.07.002

26 March 2024

11

1 reference

10.1016/J.CTRV.2003.07.002

https://api.crossref.org/works/10.1016/J.CTRV.2003.07.002

26 March 2024

Somatostatin analogue phase I trials in neuroendocrine neoplasms.

12

1 reference

10.1016/J.CTRV.2003.07.002

https://api.crossref.org/works/10.1016/J.CTRV.2003.07.002

26 March 2024

Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors

13

1 reference

10.1016/J.CTRV.2003.07.002

https://api.crossref.org/works/10.1016/J.CTRV.2003.07.002

26 March 2024

Neuroendocrine tumor markers

14

1 reference

10.1016/J.CTRV.2003.07.002

https://api.crossref.org/works/10.1016/J.CTRV.2003.07.002

26 March 2024

Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers

15

1 reference

10.1016/J.CTRV.2003.07.002

https://api.crossref.org/works/10.1016/J.CTRV.2003.07.002

26 March 2024

Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group.

16

1 reference

10.1016/J.CTRV.2003.07.002

https://api.crossref.org/works/10.1016/J.CTRV.2003.07.002

26 March 2024

Interferon-alpha 2b, with or without prior hepatic artery embolization: clinical response and survival in mid-gut carcinoid patients. The Norwegian carcinoid study

17

1 reference

10.1016/J.CTRV.2003.07.002

https://api.crossref.org/works/10.1016/J.CTRV.2003.07.002

26 March 2024

Drug therapy in metastatic neuroendocrine tumors of the gastroenteropancreatic system.

19

1 reference

10.1016/J.CTRV.2003.07.002

https://api.crossref.org/works/10.1016/J.CTRV.2003.07.002

26 March 2024

Identifiers

10.1016/J.CTRV.2003.07.002

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44636550&oldid=2111571428"